{"id":"evo301","safety":{"commonSideEffects":[{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL5596687","moleculeType":null,"molecularWeight":"348.36"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"EVO301 works by binding to CD22 on the surface of B cells, leading to their depletion and potentially reducing B cell-mediated immune responses.","oneSentence":"EVO301 is a monoclonal antibody targeting CD22.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:37.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell acute lymphoblastic leukemia"}]},"trialDetails":[{"nctId":"NCT06723405","phase":"PHASE2","title":"Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Evommune, Inc.","startDate":"2025-02-13","conditions":"Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EVO301","genericName":"EVO301","companyName":"Evommune, Inc.","companyId":"evommune-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"EVO301 is a monoclonal antibody targeting CD22. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}